Human Genome Epidemiology Literature Finder
|
Records 1 - 13 (of 13 Records) |
| Query Trace: Neoplasms and SLC28A3[original query] |
|---|
| Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 May 30 (13): 1422-8. Visscher Henk, Ross Colin J D, Rassekh S Rod, Barhdadi Amina, Dubé Marie-Pierre, Al-Saloos Hesham, Sandor George S, Caron Huib N, van Dalen Elvira C, Kremer Leontien C, van der Pal Helena J, Brown Andrew M K, Rogers Paul C, Phillips Michael S, Rieder Michael J, Carleton Bruce C, Hayden Michael R, |
| Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenetics and genomics 2012 Feb 22 (2): 105-16. Li Liang, Schaid Daniel J, Fridley Brooke L, Kalari Krishna R, Jenkins Gregory D, Abo Ryan P, Batzler Anthony, Moon Irene, Pelleymounter Linda, Eckloff Bruce W, Wieben Eric D, Sun Zhifu, Yang Ping, Wang Liew |
| Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. European journal of cancer (Oxford, England : 1990) 2014 Mar 50 (4): 698-705. Lee Soo-Youn, Im Seock-Ah, Park Yeon Hee, Woo Sook Young, Kim Seonwoo, Choi Moon Ki, Chang Wonjin, Ahn Jin Seok, Im Young-Hyu |
| Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes. Pharmacogenomics 2014 Mar 15 (4): 433-47. Matimba Alice, Li Fang, Livshits Alina, Cartwright Cher S, Scully Stephen, Fridley Brooke L, Jenkins Gregory, Batzler Anthony, Wang Liewei, Weinshilboum Richard, Lennard Lyn |
| Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. Breast cancer research and treatment 2015 Jul 152 (1): 67-76. Vulsteke Christof, Pfeil Alena M, Maggen Charlotte, Schwenkglenks Matthias, Pettengell Ruth, Szucs Thomas D, Lambrechts Diether, Dieudonné Anne-Sophie, Hatse Sigrid, Neven Patrick, Paridaens Robert, Wildiers Ha |
| Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics 2016 Jan . Hertz Daniel L, Caram Megan V, Kidwell Kelley M, Thibert Jacklyn N, Gersch Christina, Seewald Nicholas J, Smerage Jeffrey, Rubenfire Melvyn, Henry N Lynn, Cooney Kathleen A, Leja Monika, Griggs Jennifer J, Rae James |
| A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer. Oncotarget 2017 Nov 8 (57): 96893-96902. Jo Jung Ki, Oh Jong Jin, Kim Yong Tae, Moon Hong Sang, Choi Hong Yong, Park Seunghyun, Ho Jin-Nyoung, Yoon Sungroh, Park Hae Young, Byun Seok-S |
| Correction: A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer. Oncotarget 2018 8 9 (61): 31938. Jo Jung Ki, Oh Jong Jin, Kim Yong Tae, Moon Hong Sang, Choi Hong Yong, Park Seunghyun, Ho Jin-Nyoung, Yoon Sungroh, Park Hae Young, Byun Seok-S |
| Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer. Cancer science 2019 Sep . Makino Yoshinori, Makihara-Ando Reiko, Ogawa Takanori, Sato Hitoshi, Goto Yasushi, Kanda Shintaro, Horinouchi Hidehito, Fujiwara Yutaka, Ohe Yuichiro, Yamamoto Nobo |
| Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Feb . Peddi Parvin F, Fasching Peter A, Liu Duan, Quinaux Emmanuel, Robert Nicholas J, Valero Vicente, Crown John, Falkson Carla, Brufsky Adam, Cunningham Julie M, Weinshilboum Richard M, Pienkowski Tadeusz, Eiermann Wolfgang, Martín Miguel, Bee Valerie, Wang Xiaoyan, Wang Liewei, Yang Eric, Slamon Dennis J, Hurvitz Sara |
| Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study. JMIR research protocols 2022 2 11 (2): e27898. Zolk Oliver, von dem Knesebeck Annika, Graf Norbert, Simon Thorsten, Hero Barbara, Abdul-Khaliq Hashim, Abd El Rahman Mohamed, Spix Claudia, Mayer Benjamin, Elsner Susanne, Gebauer Judith, Langer Thorst |
| Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study. JCO precision oncology 2023 3 7 e2200580. Larkin Trisha, Kashif Reema, Elsayed Abdelrahman H, Greer Beate, Mangrola Karna, Raffiee Roya, Nguyen Nam, Shastri Vivek, Horn Biljana, Lamba Jatinder |
| Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients. British journal of clinical pharmacology 2023 1 . Nyangwara Vincent Aketch, Mazhindu Tinashe, Chikwambi Zedias, Masimirembwa Collen, Campbell Thomas B, Borok Margaret, Ndlovu Ntoko |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 29, 2023
- Content source: